IL158235A0 - A pharmaceutical tablet having high sulfhydryl-based matrix metalloproteinase inhibitor content - Google Patents
A pharmaceutical tablet having high sulfhydryl-based matrix metalloproteinase inhibitor contentInfo
- Publication number
- IL158235A0 IL158235A0 IL15823502A IL15823502A IL158235A0 IL 158235 A0 IL158235 A0 IL 158235A0 IL 15823502 A IL15823502 A IL 15823502A IL 15823502 A IL15823502 A IL 15823502A IL 158235 A0 IL158235 A0 IL 158235A0
- Authority
- IL
- Israel
- Prior art keywords
- matrix metalloproteinase
- based matrix
- pharmaceutical tablet
- metalloproteinase inhibitor
- inhibitor content
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28668201P | 2001-04-26 | 2001-04-26 | |
| US28687001P | 2001-04-26 | 2001-04-26 | |
| PCT/US2002/012915 WO2002087548A1 (en) | 2001-04-26 | 2002-04-23 | A pharmaceutical tablet having a high api content |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL158235A0 true IL158235A0 (en) | 2004-05-12 |
Family
ID=26964005
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15841202A IL158412A0 (en) | 2001-04-26 | 2002-04-23 | A method for increasing the compactability of an active ingredient and a process for producing a solid dosage form having a high active ingredient drug load |
| IL15823502A IL158235A0 (en) | 2001-04-26 | 2002-04-23 | A pharmaceutical tablet having high sulfhydryl-based matrix metalloproteinase inhibitor content |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15841202A IL158412A0 (en) | 2001-04-26 | 2002-04-23 | A method for increasing the compactability of an active ingredient and a process for producing a solid dosage form having a high active ingredient drug load |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20040175419A1 (xx) |
| EP (2) | EP1390018A1 (xx) |
| JP (2) | JP2004530679A (xx) |
| KR (1) | KR20040036686A (xx) |
| CN (2) | CN1523981A (xx) |
| BR (2) | BR0209199A (xx) |
| CA (2) | CA2445290A1 (xx) |
| CZ (2) | CZ20032901A3 (xx) |
| HU (2) | HUP0400377A2 (xx) |
| IL (2) | IL158412A0 (xx) |
| MX (2) | MXPA03009676A (xx) |
| PL (2) | PL367262A1 (xx) |
| WO (2) | WO2002087548A1 (xx) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE327744T1 (de) | 2001-03-20 | 2006-06-15 | Sanol Arznei Schwarz Gmbh | Neue verwendung von peptidverbindungen bei der behandlung von nicht-neuropathischem entzündungsschmerz |
| ATE228358T1 (de) | 2001-03-21 | 2002-12-15 | Sanol Arznei Schwarz Gmbh | Neue verwendung einer klasse von peptidverbindungen zur behandlung von allodynie oder andere arten von chronischen oder phantomschmerzen |
| US20080182801A1 (en) | 2003-12-22 | 2008-07-31 | Btg International Limited | Core 2 glcnac-t inhibitors |
| GB0513881D0 (en) | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors III |
| GB0329667D0 (en) | 2003-12-22 | 2004-01-28 | King S College London | Core 2 GlcNAc-T inhibitor |
| EP1604656A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS) |
| BRPI0514721A (pt) | 2004-08-27 | 2008-06-24 | Sanol Arznei Schwarz Gmbh | uso de compostos de peptìdeos para tratar dor de cáncer ósseo, dor induzida por quimioterapia e nucleosìdeo |
| GB0513888D0 (en) | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors II |
| GB0513883D0 (en) | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Diagnosis of Atherosclerosis |
| KR101518427B1 (ko) | 2006-06-15 | 2015-05-08 | 유씨비 파르마 게엠베하 | 상승적 항경련 효과를 갖는 약제학적 조성물 |
| GB0722484D0 (en) * | 2007-11-15 | 2007-12-27 | Ucl Business Plc | Solid compositions |
| JP2013528214A (ja) | 2010-06-07 | 2013-07-08 | テリック，インコーポレイテッド | 結晶性エザチオスタット塩酸塩非溶媒和物ｄ型の調製 |
| CN102917694A (zh) * | 2010-06-07 | 2013-02-06 | 泰立克公司 | 依泽替米贝的片剂制剂 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4476248A (en) * | 1983-02-28 | 1984-10-09 | The Upjohn Company | Crystallization of ibuprofen |
| WO1993012768A1 (en) * | 1991-12-30 | 1993-07-08 | Fmc Corporation | Microcrystalline cellulose spheronization composition |
| WO1997012902A1 (en) * | 1995-10-05 | 1997-04-10 | Darwin Discovery Limited | Thio-substituted peptides as inhibitors for metalloproteinases and tnf liberation |
-
2002
- 2002-04-23 JP JP2002584894A patent/JP2004530679A/ja not_active Withdrawn
- 2002-04-23 PL PL02367262A patent/PL367262A1/xx not_active Application Discontinuation
- 2002-04-23 CA CA002445290A patent/CA2445290A1/en not_active Abandoned
- 2002-04-23 BR BR0209199-2A patent/BR0209199A/pt unknown
- 2002-04-23 MX MXPA03009676A patent/MXPA03009676A/es unknown
- 2002-04-23 JP JP2002585919A patent/JP2005505501A/ja active Pending
- 2002-04-23 HU HU0400377A patent/HUP0400377A2/hu unknown
- 2002-04-23 CA CA002445702A patent/CA2445702A1/en not_active Abandoned
- 2002-04-23 CN CNA028089944A patent/CN1523981A/zh active Pending
- 2002-04-23 WO PCT/US2002/012915 patent/WO2002087548A1/en not_active Application Discontinuation
- 2002-04-23 HU HU0303860A patent/HUP0303860A3/hu unknown
- 2002-04-23 MX MXPA03009689A patent/MXPA03009689A/es unknown
- 2002-04-23 US US10/475,959 patent/US20040175419A1/en not_active Abandoned
- 2002-04-23 EP EP02723952A patent/EP1390018A1/en not_active Withdrawn
- 2002-04-23 CN CNA02812779XA patent/CN1520283A/zh active Pending
- 2002-04-23 WO PCT/US2002/013055 patent/WO2002088664A2/en not_active Application Discontinuation
- 2002-04-23 PL PL02373548A patent/PL373548A1/xx not_active Application Discontinuation
- 2002-04-23 BR BR0209155-0A patent/BR0209155A/pt not_active Application Discontinuation
- 2002-04-23 IL IL15841202A patent/IL158412A0/xx unknown
- 2002-04-23 CZ CZ20032901A patent/CZ20032901A3/cs unknown
- 2002-04-23 EP EP02728982A patent/EP1390011A2/en not_active Withdrawn
- 2002-04-23 US US10/476,047 patent/US20040208924A1/en not_active Abandoned
- 2002-04-23 CZ CZ20032902A patent/CZ20032902A3/cs unknown
- 2002-04-23 KR KR10-2003-7013698A patent/KR20040036686A/ko not_active Application Discontinuation
- 2002-04-23 IL IL15823502A patent/IL158235A0/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004530679A (ja) | 2004-10-07 |
| BR0209155A (pt) | 2004-10-05 |
| KR20040036686A (ko) | 2004-04-30 |
| HUP0303860A2 (hu) | 2004-03-29 |
| IL158412A0 (en) | 2004-05-12 |
| EP1390018A1 (en) | 2004-02-25 |
| CN1523981A (zh) | 2004-08-25 |
| HUP0400377A2 (en) | 2007-09-28 |
| US20040208924A1 (en) | 2004-10-21 |
| PL367262A1 (en) | 2005-02-21 |
| CA2445702A1 (en) | 2002-11-07 |
| PL373548A1 (en) | 2005-09-05 |
| CZ20032901A3 (en) | 2004-07-14 |
| WO2002088664A2 (en) | 2002-11-07 |
| WO2002088664A3 (en) | 2003-08-21 |
| HUP0303860A3 (en) | 2005-05-30 |
| MXPA03009676A (es) | 2004-02-12 |
| BR0209199A (pt) | 2006-02-07 |
| WO2002087548A1 (en) | 2002-11-07 |
| CZ20032902A3 (cs) | 2004-01-14 |
| MXPA03009689A (es) | 2004-02-12 |
| JP2005505501A (ja) | 2005-02-24 |
| EP1390011A2 (en) | 2004-02-25 |
| CN1520283A (zh) | 2004-08-11 |
| US20040175419A1 (en) | 2004-09-09 |
| CA2445290A1 (en) | 2002-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1361873A4 (en) | Matrix metalloproteinase INHIBITORS | |
| HK1060047A1 (en) | Matrix metalloproteinase inhibitors | |
| AU2002244154A1 (en) | Divalproex sodium tablets | |
| AP2002002409A0 (en) | Pharmaceutical compositions comprising a hmg reductase inhibitor | |
| HK1073253A1 (en) | High drug load tablet | |
| AU152289S (en) | A computer | |
| GB0101379D0 (en) | A computer | |
| AU152302S (en) | A computer | |
| HUP0400328A3 (en) | Metalloproteinase inhibitor azoles and pharmaceutical compositions containing them | |
| IL146632A0 (en) | Pharmaceutical tablets | |
| IL158235A0 (en) | A pharmaceutical tablet having high sulfhydryl-based matrix metalloproteinase inhibitor content | |
| HK1062896A1 (en) | Swallow tablet comprising paracetemol | |
| AU2003257102A8 (en) | Pharmaceutical dosage form comprising a sulfite compound | |
| HUP0302904A3 (en) | Matrix metalloproteinase inhibitors | |
| IL164755A0 (en) | Pharmaceutical composition containing a reversibleprotein pump inhibitor | |
| AU152293S (en) | A computer | |
| PL376744A1 (pl) | Tabletki farmaceutyczne zawierające tibolon i powłoczkę | |
| AU2001271068A1 (en) | Matrix metalloprotease inhibitors | |
| HRP20050430A2 (en) | Pharmaceutical tablets containing tibolone and a coating | |
| AU2002235225A1 (en) | Matrix metalloproteinase inhibitors | |
| AU144411S (en) | A tablet | |
| AU144014S (en) | A tablet | |
| AU2002335440A1 (en) | Matrix metalloprotease inhibitor | |
| AU2002233436A1 (en) | Fenofibrate tablets | |
| CA89992S (en) | Tablet |